Journal Pre-proof In vivo confocal microscopy of dermoscopic suspicious lesions in Xeroderma Pigmentosum Patients – A Cross-sectional Study Lílian Kelly Faria Licarião Rocha, MD, Paula Ferreira, MD, João Avancini, MD, Silvia V. Lourenço, PhD, Caroline F. Barbosa, MD, Caroline Colacique, MD, Cyro Festa Neto, PhD PII:
S0190-9622(19)33293-1
DOI:
https://doi.org/10.1016/j.jaad.2019.12.018
Reference:
YMJD 14069
To appear in:
Journal of the American Academy of Dermatology
Received Date: 2 July 2019 Revised Date:
1 November 2019
Accepted Date: 11 December 2019
Please cite this article as: Rocha LKFL, Ferreira P, Avancini J, Lourenço SV, Barbosa CF, Colacique C, Neto CF, In vivo confocal microscopy of dermoscopic suspicious lesions in Xeroderma Pigmentosum Patients – A Cross-sectional Study, Journal of the American Academy of Dermatology (2020), doi: https://doi.org/10.1016/j.jaad.2019.12.018. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
1
TITLE: In vivo confocal microscopy of dermoscopic suspicious
2
lesions in Xeroderma Pigmentosum Patients – A Cross-sectional
3
Study
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
AUTHORS: Rocha, L.; Ferreira, P.; Avancini J.; Lourenço V. S.; Barbosa F. C.; Colacique C.; Festa-Neto C. Dermatology Department of Hospital das Clínicas of São Paulo University, Brazil
-Lílian Kelly Faria Licarião Rocha: MD / Researcher and Dermatologist at Department of Dermatology, Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -Paula Ferreira: MD / Dermatologist at Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -João Avancini: MD / Dermatologist at Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -Silvia V Lourenço: PhD / Dentist at Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -Caroline F Barbosa: MD / Dermatologist at Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -Caroline Colacique: MD / Dermatologist at Hospital das Clínicas of São Paulo University, São Paulo, Brazil. -Cyro Festa Neto: PhD/ Professor at Department of Dermatology, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
CORRESPONDING AUTHOR:
Lílian Rocha E-mail:
[email protected] Address: Av. Dr. Enéas de Carvalho, 255 São Paulo - Brazil
WORD COUNT: Capsule Summary: 42 Abstract: 199 Article: 1960 NUMBER OF FIGURES: 1 (1a, 1b, 1c, 1d) NUMBER OF TABLES: 2 NUMBER OF REFERENCES: 17 Financial disclosure: none reported Funding/support: this study had no funding and financial support. The authors have no conflict of interest to disclose.
47 48 49
ABSTRACT
50 51
INTRODUCTION: Xeroderma pigmentosum (XP) is a rare genetic disease that is
52
characterized by extreme photosensitivity, resulting in a higher incidence of cutaneous
53
tumors. Reflectance confocal microscopy (RCM) is a noninvasive imaging method for
54
diagnosing cutaneous lesions.
55
OBJECTIVE: To explore the application of RCM in the follow-up of XP patients.
56
MATERIALS AND METHODS: XP patients underwent RCM for suspicious lesions from
57
January 2010 to April 2019. Lesions with malignant RCM features were excised, and the
58
results were compared with their histopathological features. Benign lesions on RCM were
59
monitored every 3 months. We recorded the confocal features that were related to
60
malignancy and specifically to melanoma.
61
RESULTS: A total of 61 suspicious lesions from 13 XP patients were included. Thirty-three
62
lesions (54%) were malignant (14 melanomas, 15 basal cell carcinomas, and 4 squamous cell
63
carcinomas).
64
Nonvisible papillae (OR: 11.8 [95% CI 2.6-53.1], p:0.001) and atypical cells at the dermal-
65
epidermal junction (OR: 11.7 [95% CI 2.7-50.3], p:0.001) were independent predictors of
66
malignancy.
67
LIMITATIONS: The limited number of patients and lesions. Most cases were
68
retrospectively included, and some did not undergo a histological analysis.
69
CONCLUSIONS: RCM is a valuable tool in the follow-up of XP patients, reducing the need
70
for excisions by 35%.
71 72
73 74 75
ABBREVIATIONS AND ACRONYMS:
76
BCC: Basal cell carcinoma
77
DEJ: Dermal-epidermal junction
78
OR: Oddis ratio
79
RCM: Reflectance confocal microscopy
80
RCM melanoma score: Confocal microscopic score for melanoma
81
RCM LM score: Confocal microscopic score for lentigo maligna
82
SCC: Squamous cell carcinoma
83
TBP: Total-body photographs
84
XP: Xeroderma pigmentosum
85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
106
INTRODUCTION:
107
Xeroderma pigmentosum (XP) is a rare disorder in which UV radiation induced
108
damage repair is defective and is characterized by photosensitivity, with a significant
109
predilection for skin burning following minimal sun exposure, abnormal lentiginosis (freckle-
110
like pigmentation) on sun-exposed areas and resulting areas of increased or decreased
111
pigmentation, skin aging, and multiple skin cancers.1 XP patients are estimated to have a
112
10,000-fold greater risk of nonmelanoma skin cancer and a 2,000-fold higher risk for
113
melanoma under the age of 20 years compared with the general population.2
114
The prognosis of XP patients depends on UV photoprotection, a strict clinical follow-
115
up, and the early diagnosis and surgical treatment of skin tumors. Unfortunately, the clinical
116
diagnosis of skin tumors at an early stage and the discrimination between malignant and
117
benign lesions are difficult due to the presence of severe UV-induced skin damage and
118
general actinic lesions.
119
In vivo reflectance confocal microscopy (RCM) is a novel technique that can be used
120
to examine the epidermis and papillary dermis noninvasively with cellular resolution3.
121
Dermoscopy plus RCM is significantly more sensitive and specific than dermoscopy alone in
122
the diagnosis of melanoma and nonmelanoma tumors4, 5, 6,7.
123
This study examined whether RCM in the follow-up of XP patients improves the
124
accuracy of the diagnosis of malignant lesions and reduces the number of unnecessary
125
excisions in this challenging population.
126 127
METHODS
128
This cross-sectional study was performed from January 2010 to April 2019. XP
129
patients who were followed by the tertiary center in the Dermatology Department of Hospital
130
das Clínicas, São Paulo University (Brazil) were enrolled. The study was approved by the
131
national and local ethics committees (CEP - CAAE: 98968918.0.0000.0068, parecer:
132
3.163.255).
133
XP patients were followed every 3 months with a complete cutaneous surface
134
examination, digital dermoscopy, and total-body photographs (TBPs) as standard care. We
135
added an evaluation by RCM for suspicious lesions in XP patients.
136
Dermoscopic images and TBPs were captured using the bodystudio ATBM® method
137
(Fotofinder system, Germany). RCM images were acquired primarily by a Vivascope 3000
138
(Caliber ID, Rochester, NY), which uses an 830-nm laser with a maximum power of 20 mW.
139
Patient demographics and tumor characteristics were recorded, and 2 independent
140
investigators (L.R. and P.F.) evaluated all clinical, dermoscopic, and RCM images. All
141
lesions with at least 1 of the following criteria were considered to be suspicious: any
142
dermoscopic feature that was related to malignancy per previous dermoscopic criteria for
143
melanocytic lesions, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) 8, 9, 10,
144
11
; any significant change on the TBP; and new lesions on the TBP.
145
RCM analysis was based on microscopic features for melanoma per Pellacani et al.4
146
and Guitera et al.5, and the scores for melanoma (RCM melanoma score4) and lentigo
147
maligna (RCM LM score5) were calculated for each lesion. RCM features for BCC per
148
Guitera P et al.12 and Longo C et al.13 and RCM features for SCC per Manfredini M et al.14
149
and Shahriari N et al.15 were included in this study.
150
All suspicious lesions were evaluated by RCM, and excisions were performed for
151
lesions that were suspicious by RCM. Histological results were compared with the evaluation
152
by RCM. Lesions classified as benign on RCM were not excised and they were monitored
153
every 3 months by dermoscopy and RCM.
154 155
Statistical analysis
156
Data were analyzed using SPSS (version 25.0.0, Windows©). Fisher’s exact and Pearson chi-
157
square tests were used to analyze the association between quantitative factors. Descriptive
158
statistics were calculated for clinical, dermoscopic, and confocal features.
159
Three scenarios were considered in the statistical analysis: “malignant lesions,” which
160
included melanomas, BCCs, and SCCs, “melanoma diagnosis,” which comprised only
161
melanocytic malignant lesions, and “BCC diagnosis”. Logistic regression models were used
162
to test the associations of confocal features with malignancy, the diagnosis of melanoma and
163
BCC diagnosis. Odds ratios (ORs) with p <0.05 were considered to be statistically
164
significant.
165 166
RESULTS
167
A total of 61 suspicious lesions from 13 XP patients were included. Nine patients
168
(69%) were female, and the median age was 27.3 years (range: 9-69 years), with half of the
169
patients aged under 20. The average number of lesions per patient was 5 (range: 1-11
170
lesions), and the main areas that were affected were the face and neck (54%), trunk (24%),
171
and lips and oral area (13%).
172
Of the 61 lesions, 32 were included due to having suspicious dermoscopic features on
173
initial evaluation, 25 presented changes during the dermoscopic monitoring, and 4 were new
174
lesions on the TBP.
175
Thirty-three lesions (54%) were diagnosed as being malignant (14 melanomas, 15
176
BCC, and 4 SCC). Of the 14 melanomas, 13 lesions were in situ and 1 melanoma had a
177
Breslow thickness of 0.2 mm.
178
Twenty-eight lesions were classified as benign (with no previously described feature
179
of malignancy by RCM4, 5, 12, 13, 14, 15): 20 lesions were not excised and were then followed
180
with dermoscopy, TBP, and RCM every 3 months (median follow-up time: 17 months, range
181
5-324 months) but did not present with any significant change. The other 8 benign lesions
182
were excised: 7 were suspicious by RCM (the histological diagnoses were: 5 lesions were
183
atypical intradermal melanocytic hyperplasia, 1 was a junctional melanocytic nevus that was
184
associated with actinic keratosis, and 1 was a dysplastic junctional nevus with pigment
185
incontinence), and the remaining benign lesion was excised as requested by the patient (the
186
histological diagnosis was seborrheic keratosis).
187
The confocal examination revealed features that were related to cutaneous
188
malignancy: epidermal disarray (OR: 10.0 [95% CI: 2.0-50.6], p:0.005), nonvisible papillae
189
(OR: 12.0 [95% CI: 3.3-43.3], p<0.001), atypical cells at the dermal-epidermal junction
190
(DEJ) (OR: 11.8 [95% CI: 3.4-40.8], p<0.001), distribution of bright cells at the DEJ (OR:
191
5.0 [95% CI: 1.7-14.9], p:0.004), dermal involvement (OR: 25.4 [95% CI: 3.1-209.5],
192
p:0.003), presence of pleomorphic cells (OR: 9.4 [95% CI: 2.9-30.2], p<0.001), and linear-
193
horizontal vessels (OR: 8.6 [95% CI: 1.0-74.1], p=0.049). The presence of melanophages
194
(OR: 0.2 [95% CI: 0.1-0.6], p=0.005) and the “cord-like sign”—polycyclic papillae, as
195
circumvolution of edged papillae (OR: 0.2 [95%CI: 0.1-0.8], p=0.019)—were inversely
196
associated with cutaneous malignancy (TABLE I).
197
The RCM features that were statistically associated with a melanoma diagnosis were:
198
pagetoid cells (OR: 5.9 [95%CI: 1.1-30.5], p=0.035), adnexal spread (OR: 9.0 [95%CI: 1.4-
199
56.1], p=0.019), atypical cells at the DEJ (OR: 5.3 [95%CI: 1.1-26.2], p=0.042), nests of
200
melanocytes (OR: 18.4 [95%CI: 1.9-182.7], p=0.013), irregular distribution of bright cells
201
(OR: 9.7 [95%CI: 1.9-48.3], p=0.006), and irregular distribution of the pigmentation (OR:
202
5.3 [95%CI: 1.1-26.2], p=0.042). The sensitivity and specificity of RCM melanoma score4
203
were 85.7% and 46.8% for a melanoma diagnosis, compared with 57.1% and 76.6% of RCM
204
LM score5, respectively. TABLE II
205
Confocal analysis of BCC lesions showed that most previously described RCM
206
features for BCC15,16 were present in these lesions and were statistically associated with a
207
BCC diagnosis: plump-bright cells (OR: 60.5 [95%CI: 9.8-373.9], p<0.001), streaming
208
epidermis (OR: 33.0 [95%CI: 5.7-190.6], p<0.001), dark silhouette and clefting (OR: 44.0
209
[95%CI: 7.4-260.3], p<0.001), linear telangiectasia-like horizontal vessel (OR: 19.3
210
[95%CI:3.4-110.0], p=0.001), and peripheral palisading (OR:11.0 [95%CI: 1.9-65.1],
211
p=0.08). Of the 15 BCC lesions, 40% (6/15) were reported histologically as pigmented. By
212
dermoscopy, most of the BCC lesions were pigmented: 86.7% (13/15) presented with
213
irregular globules and dots, 73.3% (11/15) presented with an asymmetrical blotch, and 60%
214
(9/15) were grey.
215
Some cases of melanoma showed RCM features that resembling BCC: 2 cases
216
(14,3%) had streaming epidermis, plump-bright cells, peripheral palisading, dark silhouette,
217
and clefting, and 1 case (7%) showed a linear telangiectasia-like horizontal vessel.
218
Among the 4 SCC cases, 2 lesions were histological in situ and 2 were superficial
219
invasive. All SCC cases presented with epidermal disarray and looping vessels, 3 cases
220
presented with round circles with a bright white rim and inflammation, and 2 cases harbored
221
erosion and dendritic cells.
222
All 61 lesions in this study were suspicious lesions on dermoscopy. They would have
223
been removed, regardless of intervention by RCM. Only lesions suspicious on RCM (total of
224
40/61) were removed and had histological analysis. The remaining 21 lesions were not
225
excised and were monitored by dermoscopy and RCM. During monitoring these lesions
226
presented no changes and they were classified as benign. Ultimately, 65% (40/61) of the
227
lesions were classified as being malignant by RCM and were excised, decreasing the number
228
of excisions that was needed by 35%.
229 230
Multivariate analysis
231
The multivariate logistic regression model showed that by RCM, nonvisible papillae (OR:
232
11.8 [95% CI 2.6-53.1], p:0.001) and atypical cells at the DEJ (OR: 11.7 [95% CI 2.7-50.3],
233
p:0.001) were independent predictors of malignancy.
234
235 236 237
DISCUSSION
238
We have reported confocal features that are related to suspicious lesions in XP
239
patients. Most of our patients were female, and half of them were aged under 20 years. The
240
early onset of skin cancer is one of the main characteristics of XP, and the average age at the
241
first diagnosis of a cutaneous tumor is 8 years1. As expected, our sample presented with
242
severe sun-induced damage with multiple hyperpigmented, hypopigmented, and scaly
243
lesions, making the clinical diagnosis of cutaneous malignancy difficult.
244
Dermoscopy, TBP, and RCM increase the diagnostic accuracy of malignancies,
245
particularly melanoma3, 4, 5, 6, 7, 16. We suggest that the combination of these noninvasive tools
246
will improve the accuracy of such diagnoses in XP patients and should be implemented in the
247
follow-up of XP patients.
248
Harris Green et al.17 reported a case with XP who was followed monthly by clinical
249
and dermoscopic examination in association with TBPs. They reported that the thickest
250
melanoma in their series was 1.07 mm and that the mean Breslow thickness was 0.18mm.
251
Most melanomas in our series were in situ, and only 1 melanoma had a Breslow thickness of
252
0.2 mm. We suggest that our approach of combining total-body cutaneous examination, TBP,
253
and dermoscopy every 3 months, in association with RCM examination, for every suspicious
254
lesion will improve the early detection of melanoma in XP patients.
255
The most important malignant differential diagnosis of melanoma was pigmented
256
BCC in our series. Most BCC lesions presented with irregular globules and dots,
257
asymmetrical blotches, and grey color, complicating the clinical differentiation of these 2
258
diagnoses. RCM was a good approach for differentiating melanoma from pigmented BCC in
259
this study. The RCM features that have been described for BCC15,16 were seen primarily in
260
BCC tumors. Further, pleomorphic cells and linear-horizontal vessels were predictors of
261
malignancy but not melanoma.
262
The sensitivity of the RCM melanoma score4 in this series was lower compared with
263
Pellacani et al.4 (85.7% and 96.3%, respectively), as was the specificity (46.8% vs 52.1%) for
264
a melanoma diagnosis. However, Pellacani et al. 4 described the score only for melanocytic
265
lesions in the general population.
266
Our approach in XP patients led to a correct diagnosis of malignancy in 100% of
267
patients (all 33 cases of malignancy were diagnosed correctly by RCM), with a positive
268
predictive value of 82.5% (7 lesions that were classified as malignant by RCM were benign
269
by histology), and the number of excisions that was reduced by 35%. Notably, the false-
270
positive cases (lesions that were classified as malignant by RCM but nonmalignant by
271
histology) in our series were lesions with cytological atypia.
272
Our study had several limitations. The sample of XP patients was small, and the
273
number of malignant lesions was also limited. Most benign lesions did not undergo a
274
histological evaluation and were followed using noninvasive techniques. Most cases were
275
evaluated retrospectively.
276
There has been no previous report on the use of RCM in clinical decision-making for
277
XP patients. We found that RCM, in association with total-body cutaneous examination,
278
TBP, and dermoscopy, in XP patients improves the accuracy of the diagnosis of malignancy
279
and can help differentiate the main cutaneous diagnosis, leading to a lower rate of excision
280
and perhaps the early detection of melanoma. Future research should determine whether TBP
281
and dermoscopy every 3 months, combined with RCM, accelerates the early detection of
282
melanoma in XP patients.
283 284 285
286 287 288
REFERENCES:
289 290
1. Alan R Lehmann, David McGibbon and Miria Stefanini. Xeroderma pigmentosum.
291
Orphanet Journal of Rare Diseases 2011, 6:70.
292 293
2. Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma
294
pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011, 48:168-
295
176.
296 297
3. Rajadhyaksha M, Grossman M, Esterowitz D, et al. In vivo confocal scanning laser microscopy of
298
human skin: melanin provides strong contrast. J Invest Dermatol. 1995 Jun;104(6):946-52.
299 300
4. Giovanni Pellacani, Pascale Guitera, Caterina Longo et al. The Impact of In Vivo Reflectance
301
Confocal Microscopy for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions.
302
Journal of Investigative Dermatology (2007) 127, 2759–2765.
303 304
5. Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on
305
the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of
306
the face. J Invest Dermatol. 2010 Aug;130(8):2080-91. doi: 10.1038/jid.2010.84. Epub 2010 Apr 15.
307 308
6. Rao BK, Mateus R, Wassef C et al. In vivo confocal microscopy in clinical practice: comparison
309
of bedside diagnostic accuracy of a trained physician and distant diagnosis of an expert reader. J
310
Am Acad Dermatol. 2013 Dec;69(6):e295-300. doi: 10.1016/j.jaad.2013.07.022. Epub 2013 Sep 13.
311
312
7. Alarcon I, Carrera C, Palou J et al. Impact of in vivo reflectance confocal microscopy on the
313
number needed to treat melanoma in doubtful lesions. Br J Dermatol. 2014 Apr;170(4):802-8. doi:
314
10.1111/bjd.12678.
315 316
8. Argenziano G, Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions. Results of a
317
consensus meeting via the internet. J Am Acad Dermatol 2003; 48: 679-93.
318 319
9: Menzies SW, Westerhoff K, Rabinovitz H et al. Surface microscopy of pigmented basal cell
320
carcinoma. Arch Dermatol 2000; 136: 1012–16.
321 322
10: Zalaudek I, Giacomel J, Schmid K et al. Dermatoscopy of facial actinic keratosis, intraepidermal
323
carcinoma, and invasive squamous cell carcinoma: A progression model. J Am Acad Dermatol 2012;
324
Volume 66, Issue 4, Pages 589–597
325 326
11. Lallas A, Tschandl P, Kyrgidis A et al. Dermoscopic clues to differentiate facial lentigo maligna
327
from pigmented actinic keratosis. Br J Dermatol. 2016 May;174(5):1079-85. doi: 10.1111/bjd.14355.
328 329
12. Guitera P, Menzies S, Longo C et al. In Vivo Confocal Microscopy for Diagnosis of Melanoma
330
and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically
331
Equivocal Cases. Journal of Investigative Dermatology (2012), Volume 132
332 333
13. Longo C, Lallas A, Kyrgidis A et al. Classifying distinct basal cell carcinoma subtype by means
334
of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol, October 2014; Volume
335
71, Issue 4, Pages 716–724.
336
337
14. Manfredini M, Longo C, Ferrari B et al. Dermoscopic and reflectance confocal microscopy
338
features of cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2017
339
Nov;31(11):1828-1833.
340 341
15. Shahriari N, Grant-Kels JM, Rabinovitz HS et al. Reflectance Confocal Microscopy Criteria of
342
Pigmented Squamous Cell Carcinoma In Situ. Am J Dermatopathol. 2018 Mar;40(3):173-179.
343 344
16. Wang SQ, Kopf AW, Koenig K. Detection of melanomas in patients followed up with total
345
cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol. 2004
346
Jan;50(1):15-20.
347 348
17. W. Harris Green; Steven Q. Wang; Armand B. Cognetta Jr et al. Total-Body Cutaneous
349
Examination, Total-Body Photography, and Dermoscopy in the Care of a Patient with Xeroderma
350
Pigmentosum and Multiple Melanomas. Arch Dermatol. 2009 Aug;145(8):910-5.
351 352 353 354
LEGEND
355
Fig 1. Xeroderma Pigmentosum. Example of lesions in Xeroderma Pigmentosum patients
356
(A) Dermoscopy of a benign lesion showing atypical network and asymmetrical globules and
357
dots (B) Confocal microscopy of the benign lesion with pigmented small bright cells and no
358
atypical cells at DEJ (C) Dermoscopy of a melanoma showing asymmetric hyperpigmented
359
follicular opening, annular-granular pattern, dust-like image and increased density of the
360
vascular network (D) Confocal microscopy of the melanoma with epidermal disarray and
361
irregular diamond-shaped large cells (>20µ) in the epidermis (pagetoid cells).
362
363 364 365 TABLE I: Confocal features related to cutaneous malignancy in Xeroderma Pigmentosum patients. Characteristics
Univariate logistic regression
p-value
OR (CI95%)
Epidermal disarray
Present
10.0 (2.0-50.6)
0.005
Irregular diamond-shaped large cells (>20µ µ) in the epidermis (pagetoid cells)
Present
6.0 (0.7-53.2)
0.108
Non-edged papillae
Present
2.6 (0.8-8.7)
0.114
Non-visible papillae
Present
12.0 (3.3-43.3)
<0.001
Atypical cells at DEJ
Present
11.8 (3.4-40.8)
<0.001
Round cells with dark nucleus at the junction size
Small (= the size of epidermal cells around)
0.2 (0.1-0.99)
0.049
Large (twice the size of epidermal cells around)
1.3 (0.3-5.5)
0.676
Mild (<5 pleomorphic2.8 (0.9-8.7) cells)
0.078
Marked (>10 pleomorphic cells)
9.3 (0.9-96.0)
0.061
Distribution of the large round cells often with dark nucleus at the junction
Irregular
5.0 (1.7-14.9)
0.004
Irregular distribution of the pigmentation
Present
2.3 (0.8-6.6)
0.120
Plump bright cells in big aggregation within the papillary dermis (Melanophages)
Present
0.2 (0.1-0.6)
0.005
Polycyclic papillae, as circumvolution of edged papillae (“Cord-like sign”)
Present
0.2 (0.1-0.8)
0.019
Dermal involvement
Present
25.4 (3.1-209.5)
0.003
Pleomorphic cells
Present
9.4 (2.9-30.2)
<0.001
Linear telangiectasia-like horizontal vessel
Present
8.6 (1.0-74.1)
0.049
RCM melanoma score4
≥2
11.8 (3.4-40.8)
<0.001
RCM LM score5
≥2
2.4 (0.8-7.5)
0.136
Pleomorphism (round, dendritic and other irregular shape of bright cells)
366 367 368 369 370 371 372 373 374 375 376 377
*DEJ: Dermal-epidermal junction; OR: odds ratio; CI95%: confidence interval 95%.
378 379 380 381 382 383
TABLE II: Confocal features related to melanoma in Xeroderma Pigmentosum patients. Univariate logistic regression
Characteristics
p-value
OR (CI95%)
Irregular diamond-shaped large cells (>20µ µ) in the epidermis
Scattered cells
6.6 (1.0-44.9)
0.054
Touching one another Absent
4.4 (0.3-76.5)
0.309
Presence of widespread large cells (>20µ µ) in the epidermis (pagetoid cells) Non-edged papillae Non-visible papillae Atypical cells at DEJ
Present
5.9 (1.1-30.5)
0.035
Present Present Present
3.2 (0.9-11.4)
0.078
5.3 (1.1-26.2)
0.042
Round cells with dark nucleus at the junction size
Small (= the size of epidermal cells around)
0.9 (0.1-6.2)
0.915
Large (twice the size epidermal cells around)
3.6 (0.7-19.9)
0.142
of
Follicular extension of pagetoid cells and/or atypical junctional cells around the follicular extension (adnexal spread)
Present
9.0 (1.4-56.1)
0.019
Distribution of the large round cells often with dark nucleus at the junction
Irregular
9.7 (1.9-48.3)
0.006
Distribution of the pigmentation
Irregular
5.3 (1.1-26.2)
0.042
Nest in the upper dermis RCM melanoma score4 RCM LM score5
Present ≥2 ≥2
18.4 (1.9-182.7) 5.3 (1.1-26.2) 4.4 (1.2-15.3)
0.013 0.042 0.021
384 385 386 387 388 389 390 391 392 393 394 395 396 397
*DEJ: Dermal-epidermal junction; OR: odds ratio; CI95%: confidence interval 95%.
CAPSULE SUMMARY: This was a cross-sectional study in Xeroderma pigmentosum (XP) patients with suspicious lesions submitted to confocal microscopy (RCM). We reported RCM features associated to malignancy and found that RCM has the potential to decrease the number of excisions in this high-risk population.